

CITATION REPORT

List of articles citing

Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance

DOI: 10.2165/00003088-200544120-00002
Clinical Pharmacokinetics, 2005, 44, 1209-25.

Source: <https://exaly.com/paper-pdf/39421331/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
160	Can pharmacogenetics help rescue drugs withdrawn from the market?. <i>Pharmacogenomics</i> , 2006 , 7, 889-908	2.08	149
159	Drug-induced changes in P450 enzyme expression at the gene expression level: a new dimension to the analysis of drug-drug interactions. <i>Xenobiotica</i> , 2006 , 36, 1013-80	2	24
158	Line-walking method for predicting the inhibition of P450 drug metabolism. 2006 , 49, 4367-73		15
157	Genetic Bases for Predisposition to Common Multifactorial Disease in Man. Part II. 2007 , 21, 385-392		2
156	Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects. 2007 , 47, 159-64		39
155	Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. 2007 , 1770, 489-94		90
154	Replicate study design in bioequivalency assessment, pros and cons: bioavailabilities of the antidiabetic drugs pioglitazone and glimepiride present in a fixed-dose combination formulation. 2007 , 47, 806-16		11
153	Nutrigenomics: concepts and applications to pharmacogenomics and clinical medicine. <i>Pharmacogenomics</i> , 2007 , 8, 369-90	2.6	32
152	Pharmacokinetic interactions with thiazolidinediones. <i>Clinical Pharmacokinetics</i> , 2007 , 46, 1-12	6.2	41
151	Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. <i>Clinical Pharmacokinetics</i> , 2007 , 46, 93-108	6.2	56
150	Cytochrome P450 reaction-phenotyping: an industrial perspective. 2007 , 3, 667-87		101
149	Pharmacogenetics of thiazolidinedione therapy. <i>Pharmacogenomics</i> , 2007 , 8, 917-31	2.6	14
148	Genotype and phenotype relationship in drug metabolism. 2007 , 81-100		5
147	Cytochrome P450: Another Player in the Myocardial Infarction Game?. 2007 , 229-280		
146	Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. 2007 , 6, 904-16		294
145	Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. <i>Clinical Pharmacology and Therapeutics</i> , 2007 , 81, 270-83	6.1	184
144	Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects. 2007 , 64, 67-74		44

143	Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination. 2007 , 64, 450-7		43
142	Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. 2007 , 116, 496-526		848
141	[CYP2D6-, CYP2C9- and CYP2C19-based dose adjustments: when do they make sense?]. 2008 , 49, 877-83		3
140	Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. 2008 , 153, 1579-86		63
139	Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. <i>Clinical Pharmacology and Therapeutics</i> , 2008 , 83, 288-92	6.1	103
138	No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. 2008 , 65, 78-86		47
137	PhRMA white paper on ADME pharmacogenomics. 2008 , 48, 849-89		58
136	Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism. 2008 , 21, 129-37		171
135	Interindividual variability in oral antidiabetic drug disposition and response: the role of drug transporter polymorphisms. 2008 , 4, 529-44		28
134	Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines. 2008 , 26, 569-87		63
133	Interindividual variability of methadone response: impact of genetic polymorphism. 2008 , 12, 109-24		102
132	Insulin, other hypoglycemic drugs, and glucagon. 2008 , 494-506		
131	PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes. 2008 , 2008, 230893		7
130	Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine. 2009 , 2, 79-91		6
129	Hypoglycemia associated with the use of levofloxacin. 2009 , 66, 1014-9		17
128	The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro. 2009 , 105, 374-9		19
127	Actions of ethnobotanically selected Cree anti-diabetic plants on human cytochrome P450 isoforms and flavin-containing monooxygenase 3. 2009 , 126, 119-26		28
126	Drug-induced liver injury: insights from genetic studies. <i>Pharmacogenomics</i> , 2009 , 10, 1467-87	2.6	80

125	Drug Metabolism. 2009 , 131-173		13
124	Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. <i>Pharmacogenomics</i> , 2009 , 10, 1781-7	2.6	71
123	Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. <i>Pharmacogenetics and Genomics</i> , 2010 , 20, 38-44	1.9	97
122	AFM study of the interaction of cytochrome P450 2C9 with phospholipid bilayers. 2010 , 163, 182-9		15
121	Evolution of capecitabine dosing in breast cancer. 2010 , 10, 130-5		10
120	Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism. 2010 , 70, 870-80		24
119	Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study. <i>Clinical Pharmacology and Therapeutics</i> , 2010 , 87, 52-6	6.1	124
118	CYP2C9*3 Loss-of-Function Allele Is Associated With Acute Upper Gastrointestinal Bleeding Related to the Use of NSAIDs Other Than Aspirin. <i>Clinical Pharmacology and Therapeutics</i> , 2010 , 87, 693-8	6.1	32
117	Genetic variants of the insulin receptor substrate-1 are influencing the therapeutic efficacy of oral antidiabetics. <i>Diabetes, Obesity and Metabolism</i> , 2010 , 12, 1106-12	6.7	11
116	The molecular mechanisms and pharmacotherapy of ATP-sensitive potassium channel gene mutations underlying neonatal diabetes. 2010 , 3, 145-61		8
115	Genetic polymorphisms in diabetes: influence on therapy with oral antidiabetics. 2010 , 60, 387-406		10
114	Symptomatic hypoglycemia associated with trimethoprim/sulfamethoxazole and repaglinide in a diabetic patient. 2010 , 44, 764-7		16
113	In silico classification of major clearance pathways of drugs with their physicochemical parameters. 2010 , 38, 1362-70		32
112	Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide. 2010 , 268, 359-66		26
111	Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. 2010 , 8, 359-72		81
110	Pharmacogenetics of Anti-Diabetes Drugs. 2010 , 3, 2610-2646		70
109	Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients. 2011 , 22, 98-102		18
108	Pharmacogénétique des antidiabétiques. 2011 , 5, 512-519		1

107	Simulation of Population Variability in Pharmacokinetics. 2011 , 59-92		
106	Pharmacokinetic Behaviors of Orally Administered Drugs. 2011 , 183-219		2
105	The pregnane X receptor agonist St John's Wort has no effects on the pharmacokinetics and pharmacodynamics of repaglinide. <i>Clinical Pharmacokinetics</i> , 2011 , 50, 605-11	6.2	15
104	Reduced catalytic activity of human CYP2C9 natural alleles for gliclazide: molecular dynamics simulation and docking studies. 2011 , 93, 1028-36		13
103	Transporter-mediated drug-drug interactions with oral antidiabetic drugs. 2011 , 3, 680-705		25
102	Advances in the treatment of type 2 diabetes mellitus. 2011 , 18, 117-52		112
101	Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 604-14	6.7	17
100	Distribution of the major cytochrome P450 (CYP) 2C9 genetic variants in a Saudi population. 2011 , 109, 111-4		13
99	Impact of genetic polymorphisms of cytochrome P450 2 C (CYP2C) enzymes on the drug metabolism and design of antidiabetics. 2011 , 194, 159-67		12
98	Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. <i>Pharmacogenomics</i> , 2011 , 12, 1161-91	2.6	53
97	Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients. <i>European Journal of Clinical Pharmacology</i> , 2011 , 67, 797-801	2.8	36
96	Population pharmacokinetic analysis of glimepiride with CYP2C9 genetic polymorphism in healthy Korean subjects. <i>European Journal of Clinical Pharmacology</i> , 2011 , 67, 889-98	2.8	13
95	Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting. <i>European Journal of Clinical Pharmacology</i> , 2011 , 67, 1223-9	2.8	24
94	Ficus deltoidea: A Potential Alternative Medicine for Diabetes Mellitus. 2012 , 2012, 632763		33
93	Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A. <i>Pharmacogenetics and Genomics</i> , 2012 , 22, 206-14	1.9	28
92	Medical appointment no-shows associated with poor glycaemic control among Taiwanese aborigines. 2012 , 20, 312-7		2
91	Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. 2012 , 33, 312-22		73
90	Optimization of the in vitro oxidative biotransformation of glimepiride as a model substrate for cytochrome p450 using factorial design. 2012 , 20, 38		0

89	Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data. 2012 , 16, 285-302		27
88	Pharmacogenetics in Drug Metabolism: Role of Phase I Enzymes. 2012 , 13-80		
87	CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects. 2012 , 8, 1549-63		32
86	Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokinetics. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2012 , 37, 105-11	2.2	20
85	No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 937-43	6.7	23
84	Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions. <i>European Journal of Pharmaceutical Sciences</i> , 2013 , 49, 819-28	5.1	17
83	The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs. <i>Clinical Pharmacokinetics</i> , 2013 , 52, 833-54	6.2	22
82	The Role of Pharmacogenomics in Diabetes, HIV Infection, and Pain Management. 2013 , 247-271		
81	Pharmacogenomics in Type 2 Diabetes Mellitus and Metabolic Disorders. 2013 , 561-573		
80	Pharmacogenetics and personalized treatment of type 2 diabetes. 2013 , 23, 154-71		26
79	Genetics of type 2 diabetes: insights into the pathogenesis and its clinical application. 2014 , 2014, 926713		49
78	Effect of CYP2C9 gene polymorphisms on response to treatment with sulfonylureas in a cohort of Egyptian type 2 diabetes mellitus patients. 2014 , 23, 341-346		2
77	Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data. <i>European Journal of Clinical Pharmacology</i> , 2014 , 70, 167-78	2.8	14
76	[The use of gliclazide in individualized sulfonylurea therapy]. 2014 , 155, 541-8		0
75	In Vitro In Silico Tools to Predict Pharmacokinetics of Poorly Soluble Drug Compounds. 2014 , 233-261		1
74	Pharmacotherapy of type 2 diabetes mellitus: an update on drug-drug interactions. 2014 , 37, 903-19		19
73	Pharmacogenomics of Oral Antidiabetic Drugs. 2014 , 683-713		0
72	Effects of Clopidogrel and Proton Pump Inhibitors on Cardiovascular Events in Patients with Type 2 Diabetes Mellitus after Drug-Eluting Stent Implantation: A Nationwide Cohort Study. 2015 , 10, e0135915		7

71	Individualized medicine enabled by genomics in Saudi Arabia. 2015 , 8 Suppl 1, S3		30
70	Life-threatening metabolic coma caused by levofloxacin. 2015 , 22, e48-51		6
69	Variation in Association Between Thiazolidinediones and Heart Failure Across Ethnic Groups: Retrospective analysis of Large Healthcare Claims Databases in Six Countries. 2015 , 38, 823-31		28
68	Stratified medicine for the use of antidiabetic medication in treatment of type II diabetes and cancer: where do we go from here?. 2015 , 277, 235-247		22
67	Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents. 2016 , 9, 17-29		11
66	Pharmacogenetic studies update in type 2 diabetes mellitus. 2016 , 7, 302-15		26
65	Association of KCNQ1 polymorphisms with gliclazide efficacy in Chinese type 2 diabetic patients. <i>Pharmacogenetics and Genomics</i> , 2016 , 26, 178-183	1.9	7
64	Precision medicine: The future in diabetes care?. 2016 , 117, 12-21		32
63	CYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patients. 2016 , 7, 764-8		9
62	Thiazolidinediones. 2016 , 851-873		
61	Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. 2016 , 68, 168-241		128
60	In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor. <i>Xenobiotica</i> , 2017 , 47, 314-323	2	3
59	Pharmacogenetics in type 2 diabetes: still a conundrum in clinical practice. <i>Expert Review of Endocrinology and Metabolism</i> , 2017 , 12, 155-158	4.1	5
58	Effects of functional CYP2C8,CYP2C9,CYP3A5,and ABCB1 genetic variants on the pharmacokinetics of insulin sensitizer pioglitazone in Chinese Han individuals. <i>Pharmacogenetics and Genomics</i> , 2017 , 27, 125-134	1.9	3
57	Reaction phenotyping to assess victim drug-drug interaction risks. <i>Expert Opinion on Drug Discovery</i> , 2017 , 12, 1105-1115	6.2	28
56	Falls: the adverse drug reaction of the elderly and the impact of pharmacogenetics. <i>Pharmacogenomics</i> , 2017 , 18, 1281-1297	2.6	15
55	Using Personalized Medicine in the Management of Diabetes Mellitus. <i>Pharmacotherapy</i> , 2017 , 37, 1131-1149	5.8	5
54	Polymorphisms of the KCNQ1 gene are associated with the therapeutic responses of sulfonylureas in Chinese patients with type 2 diabetes. <i>Acta Pharmacologica Sinica</i> , 2017 , 38, 80-89	8	14

53	Pharmacogenetic Factors That Affect Drug Metabolism and Efficacy in Type 2 Diabetes Mellitus. 2017 , 157-179		1
52	The role of K channels in cerebral ischemic stroke and diabetes. <i>Acta Pharmacologica Sinica</i> , 2018 , 39, 683-694	8	41
51	Does poor fetal growth influence the extent of fetal exposure to maternal medications?. <i>Pharmacological Research</i> , 2018 , 130, 74-84	10.2	8
50	Interaction between variants in the CYP2C9 and POR genes and the risk of sulfonylurea-induced hypoglycaemia: A GoDARTS Study. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 211-214	6.7	18
49	OATP1B3 (699G>A) and CYP2C9*2, *3 significantly influenced the transport and metabolism of glibenclamide and glipizide. <i>Scientific Reports</i> , 2018 , 8, 18063	4.9	6
48	Strategies to improve the prediction accuracy of hepatic intrinsic clearance of three antidiabetic drugs: Application of the extended clearance concept and consideration of the effect of albumin on CYP2C metabolism and OATP1B-mediated hepatic uptake. <i>European Journal of Pharmaceutical Sciences</i> , 2018 , 125, 181-188	5.1	12
47	Investigation of the molecular mechanisms of hepatic injury upon naphthalene exposure in zebrafish (<i>Danio rerio</i>). <i>Ecotoxicology</i> , 2018 , 27, 650-660	2.9	5
46	CYP2C9*3 gene variant contributes independently to glycaemic control in patients with type 2 diabetes treated with glibenclamide. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018 , 43, 768-774	2.2	8
45	Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population. <i>European Journal of Clinical Pharmacology</i> , 2018 , 74, 1021-1028	2.8	7
44	Serious Hypoglycemia and Use of Warfarin in Combination With Sulfonylureas or Metformin. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 210-218	6.1	6
43	Frequency of (, and) allelic variants, and their clinical implications, among Mexican patients with diabetes mellitus type 2 undergoing treatment with glibenclamide and metformin. <i>Biomedical Reports</i> , 2019 , 10, 283-295	1.8	2
42	The Role of Pharmacogenomics in Diabetes. 2019 , 247-269		
41	Effects of CYP2C8 and SLCO1B1 Genetic Polymorphisms on Repaglinide Pharmacokinetics: A Systematic Review and Meta-Analysis. <i>Current Drug Metabolism</i> , 2019 , 20, 266-274	3.5	4
40	Formulation and optimization of intranasal nanolipid carriers of pioglitazone for the repurposing in Alzheimer's disease using Box-Behnken design. <i>Drug Development and Industrial Pharmacy</i> , 2019 , 45, 1061-1072	3.6	32
39	A Cocktail Interaction Study Evaluating the Drug-Drug Interaction Potential of the Perpetrator Drug ASP8477 at Multiple Ascending Dose Levels. <i>Clinical Pharmacology in Drug Development</i> , 2019 , 8, 529-540	2.3	2
38	Scope of new formulation approaches in the repurposing of pioglitazone for the management of Alzheimer's disease. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019 , 44, 337-348	2.2	16
37	Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer. <i>Anti-Cancer Drugs</i> , 2019 , 30, 866-872	2.4	3
36	Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine. <i>Diabetes/Metabolism Research and Reviews</i> , 2019 , 35, e3109	7.5	34

35	Increased risk for cerebral ischemic stroke in diabetes: genetically polymorphic CYP mediated production of neuroprotective EETs and sulfonylurea metabolism in relation with K channels. <i>Acta Pharmacologica Sinica</i> , 2019 , 40, 569-570	8	2
34	Simultaneous Pharmacokinetics Estimation of Nateglinide and Pioglitazone by RP-HPLC: Computational Study to Unlock the Synergism. <i>Journal of Chromatographic Science</i> , 2020 , 58, 309-322	1.4	2
33	Knowledge, Perception, and Application of Pharmacogenomics Among Hospital Pharmacists in Saudi Arabia. <i>Risk Management and Healthcare Policy</i> , 2020 , 13, 1279-1291	2.8	7
32	The effect of co-administration of berberine, resveratrol, and glibenclamide on xenobiotic metabolizing enzyme activities in diabetic rat liver. <i>Drug and Chemical Toxicology</i> , 2020 , 1-9	2.3	1
31	Metabolic and genetic studies of glimepiride and metformin and their association with type 2 diabetes. <i>Gene Reports</i> , 2020 , 21, 100787	1.4	
30	Pharmacogenetics of hypoglycemia associated with sulfonylurea therapy in usual clinical care. <i>Pharmacogenomics Journal</i> , 2020 , 20, 831-839	3.5	3
29	The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy. <i>Vascular Health and Risk Management</i> , 2020 , 16, 241-248	4.4	4
28	Diabetes and Genetics: A Relationship Between Genetic Risk Alleles, Clinical Phenotypes and Therapeutic Approaches. <i>Advances in Experimental Medicine and Biology</i> , 2021 , 1307, 457-498	3.6	6
27	Glossary and tutorial of xenobiotic metabolism terms used during small molecule drug discovery and development (IUPAC Technical Report). <i>Pure and Applied Chemistry</i> , 2021 , 93, 273-403	2.1	1
26	Association Between the CYP2C9 Genotype and Hypoglycemia Among Patients With Type 2 Diabetes Receiving Sulfonylurea Treatment: A Meta-analysis. <i>Clinical Therapeutics</i> , 2021 , 43, 836-843.e4	3.5	5
25	Pharmacogenomics and drug metabolism. 2021 , 355-385		
24	Sources of interindividual variability. <i>Methods in Molecular Biology</i> , 2014 , 1113, 363-415	1.4	20
23	Risk of hospitalization from drug-drug interactions in the Elderly: real-world evidence in a large administrative database. <i>Aging</i> , 2020 , 12, 19711-19739	5.6	4
22	Pharmacogenetics of type 2 diabetes mellitus: An example of success in clinical and translational medicine. <i>World Journal of Translational Medicine</i> , 2014 , 3, 141	8	0
21	Molecular Modelling Analysis of the Metabolism of Troglitazone. <i>Asian Journal of Biochemistry</i> , 2007 , 2, 256-262	0.1	
20	INSULINS AND OTHER HYPOGLYCEMIC DRUGS. 2009 , 357-473		
19	Pharmacogenomics. 2010 , 435-454		
18	Combination of nateglinide with thiazolidinediones in Type 2 diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2009 , 4, 537-552	4.1	

17	Pharmacogenetics of Adverse Drug Reactions. 121-156		1
16	Genomic science: what are the implications for personalized diabetes care?. <i>Diabetes Management</i> , 2013 , 3, 225-234	0	
15	Individualizing Care in Type 2 Diabetes Mellitus. <i>Journal of Diabetes, Metabolic Disorders & Control</i> , 2014 , 1,	0.5	
14	Not Sweet At All. 2015 , 513-516		
13	Pharmacokinetic Drug Interaction between Nifedipine and Gliclazide. <i>Journal of Korean Society of Health-System Pharmacists</i> , 2016 , 33, 49-60	0	
12	INFLUENCE OF FLUCONAZOLE ON HYPOGLYCAEMIC ACTIVITY OF ORAL ANTIDIABETIC AGENTS IN HEALTHY RATS. <i>Indian Drugs</i> , 2017 , 54, 50-55	0.2	
11	Pharmakogenetik. 103-109		
10	Pharmakogenetik und Pharmakogenomik. 2008 , 314-331		
9	8. Application of Pharmacogenetics in Dose Individualization in Diabetes, Psychiatry, Cancer and Cardiology. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2008 , 19, 54-61	2.4	
8	Hibiscus sabdariffa Linn fruit derivatives as alternative agents for diabetes mellitus care: A basic insight. <i>Asia-Pacific Journal of Molecular Biology and Biotechnology</i> , 73-83	0.3	0
7	Arzneimitteltherapiesicherheit: Interaktionen der oralen Antidiabetika.		
6	No apparent pharmacokinetic interactions were found between henagliflozin: A novel sodium-glucose co-transporter 2 inhibitor and glimepiride in healthy Chinese male subjects.. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022 ,	2.2	0
5	Effects of CYP2C9*3 and *13 alleles on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects.. <i>Archives of Pharmacal Research</i> , 2021 , 45, 114	6.1	2
4	SCREENING THE INFLUENCE OF DILTIAZEM ON ORAL ANTIDIABETIC AGENTS IN EXPERIMENTAL ANIMALS. <i>Indian Drugs</i> , 2022 , 59, 54-61	0.2	
3	Effects of ginkgo leaf tablet on the pharmacokinetics of rosiglitazone in rats and its potential mechanism. <i>Pharmaceutical Biology</i> , 2022 , 60, 1190-1197	3.8	0
2	Concurrent Use of Oral Anticoagulants and Sulfonylureas in Individuals With Type 2 Diabetes and Risk of Hypoglycemia: A UK Population-Based Cohort Study. 9,		
1	Drug Dose and Therapy Individualization. 2022 , 285-301		0